T cells are central effectors in transplant rejection and anti-tumor immunity. It is thus essential to define the molecular mechanisms that govern T-cell effector programs. Dr. Chen recently discovered that interferon regulatory factor 4 (IRF4) is a key transcription factor controlling T-cell effector responses in transplantation and anti-tumor immunity. IRF4 ablation in T cells induces transplant acceptance by driving T-cell dysfunction, whereas IRF4 over expression in anti-tumor T cells inhibits cancer progression. He and his team are continuously investigating the IRF4-controlled T-cell effector programs, which will facilitate the development of novel therapeutic strategies for transplantation and cancers.
Recorded in the Houston Methodist Research Institute Ernest H. Cockrell Boardroom R2-311 on Monday, June 24, 2019.
5:52-9:52 Introduction -Dr. Li
9:55-57:50 Lecture - Dr. Chen
57:50-1:04:00 - Q&A
Introduction by: Xian Chang Li, MD, PhD
Max and Lillie Frosch Centennial Chair in Transplant Research, Immunobiology & Transplant Science Center
Professor of Transplant Immunology in Surgery, Institute for Academic Medicine
Full Member, Research Institute
Director, Immunobiology & Transplant Science Center
Weill Cornell Medical College